Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ensovibep · MP-0420

Fusion protein · Inhibitor of SARS-CoV-2 spike protein receptor-binding domain · developed by Molecular Partners

Phase 3 Most advanced trial (none active)
1 Registered trials

What is Ensovibep?

Ensovibep is a designed ankyrin repeat protein (DARPin)-based agent with three binding domains that target the same epitope region on the SARS-CoV-2 spike protein receptor-binding domain, blocking viral attachment and entry into human cells. It also carries a human serum albumin-binding domain that prolongs its half-life. It is studied in COVID-19.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MP-0420
Drug type
Fusion protein
Targets
SARS-CoV-2 spike protein receptor-binding domain, human serum albumin (ALB) (binding partner it blocks)
Mechanism
Inhibitor of SARS-CoV-2 spike protein receptor-binding domain
Pathways
viral attachment and entry into human cells
Therapy area
Infectious disease
Developer
Molecular Partners AG
In trials of
VIR
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
PV6AA88RDU

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04501978 Phase 3 Covid19 Completed VIR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Covid19

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.